B-cell-directed therapies for autoimmune disease (Q37542901)

20 August 2017

1 reference

title

B-cell-directed therapies for autoimmune disease (English)

1 reference

20 August 2017

1 reference

Gerd-Rüdiger Burmester

series ordinal

3

object named as

Gerd R Burmester

1 reference

20 August 2017

2

Andreas Radbruch

1 reference

20 August 2017

Thomas Dörner

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

7 July 2009

1 reference

Nature Reviews Rheumatology

20 August 2017

published in

1 reference

20 August 2017

volume

5

1 reference

20 August 2017

issue

8

1 reference

20 August 2017

page(s)

433-441

1 reference

An update on acute kidney injury after cardiac surgery

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Lifetime of plasma cells in the bone marrow.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Duration of humoral immunity to common viral and vaccine antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Competence and competition: the challenge of becoming a long-lived plasma cell

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Therapeutic potential for B-cell modulation in Sjögren's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

B-cell memory: are subsets necessary?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Autoreactivity by design: innate B and T lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

31 March 2020

Marginal zone B cells

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Plasma cell differentiation and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

AIRE regulates T-cell-independent B-cell responses through BAFF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Effective therapeutic use of rituximab in refractory Wegener's granulomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Antibodies and B cell memory in viral immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Persistence of memory B cells in mice deprived of T cell help.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

A checkpoint for autoreactivity in human IgM+ memory B cell development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

New approaches of B-cell-directed therapy: beyond rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

B cells as therapeutic targets for rheumatic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Measurement of radiographic joint space width in the tibiofemoral compartment of the osteoarthritic knee: comparison of standing anteroposterior and Lyon schuss views

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Pathogenic roles of B cells in human autoimmunity; insights from the clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

An open study of B lymphocyte depletion in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Drug insight: rituximab in renal disease and transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Rituximab for the treatment of type II mixed cryoglobulinemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Myasthenia gravis: emerging new therapy options

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Rituximab in refractory pemphigus vulgaris

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Epidermolysis Bullosa Acquisita following Bullous Pemphigoid, Successfully Treated with the Anti-CD20 Monoclonal Antibody Rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Rituximab in the treatment of autoimmune haematological disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Rituximab for autoimmune haemophilia: a proposed treatment algorithm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Rituximab for the treatment of acquired antibodies to factor VIII.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Association of mannose binding lectin (MBL) gene polymorphism and serum MBL concentration with characteristics and progression of systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

B-cell targeting: a novel approach to immune intervention today and tomorrow

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.141

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

31 March 2020

1 reference

12 December 2020

Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator

1 reference

12 December 2020

B cell targeted therapies: safety considerations

1 reference

12 December 2020

Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy

1 reference

12 December 2020

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

1 reference

12 December 2020

Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system

1 reference

12 December 2020

B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2009.141

1 reference

20 August 2017

1 reference